FINWIRES · TerminalLIVE
FINWIRES

Peter Warren Automotive Holdings' Wakeling Deal Faces ACCC Phase Two Competition Review

By

Peter Warren Automotive Holdings' (ASX:PWR) planned purchase of 30 new car dealership sites from Wakeling Automotive Group will undergo a detailed phase two Australian Competition and Consumer Commission (ACCC) review after the competition regulator raised concerns about the deal's potential impact on market competition, according to an Australian bourse filing on Tuesday after market hours.

The regulator did not approve the acquisition during its phase one assessment, saying that the merged company would own 25 of the region's 33 new car dealerships, per the filing. It is assessing how the deal could affect competition in new vehicle sales, as well as servicing and repair services.

The ACCC has yet to make a final decision and is inviting public submissions until June 16, the filing added. The phase two review could take up to 90 business days.

In a separate filing, Peter Warren Automotive said the companies will continue to work with the ACCC to address any concerns arising during the phase two review.

Related Articles

Asia

Nova Minerals Says New South Wales Court Approves New US Holding Entity Plan

Nova Minerals (ASX:NVA) said the Supreme Court of New South Wales has approved its proposed schemes of arrangement, enabling newly formed Nova Minerals Corp to acquire all existing shares and Nasdaq-listed warrants and become the group's new US-based holding entity, according to an Australian bourse filing on Tuesday after market hours.The schemes are expected to take legal effect on Wednesday upon lodgment of the court orders with the Australian Securities and Investments Commission, after which the company shares are anticipated to be suspended from trading on the Australian Securities Exchange, the filing added.

$ASX:NVA
Asia

Correction: Alcoa Says Tin Included in 2025 Conflict Minerals Report Either Not from Covered Countries or Scrap/Recycled Materials

(Corrects reference to the report in the first paragraph and updates throughout to include more details)Alcoa (ASX:AAI) concluded in its 2025 Conflict Minerals Disclosure report that the tin included in its products either did not originate in the Democratic Republic of the Congo or adjoining countries or from scrap or recycled materials.The company made the disclosure in a SEC filing dated May 29 and published on the Australian bourse Monday as it found that one supplier was likely to have supplied Conflict Minerals during the reporting year.Conflict minerals include coltan, cassiterite, gold, wolframite, and the derivatives tantalum, tin, and tungsten, according to the Form SD Specialized Disclosure Report.

$ASX:AAI
Asia

Everest Medicines Unit Grants Kidney Disease Development, Commercialization License

Everest Medicines (HKG:1952) unit Everest Medicines (Singapore) entered into an exclusive agreement to provide an exclusive worldwide license to Travere Therapeutics to develop and commercialize civorebrutinib, according to a Tuesday Hong Kong bourse filing.Travere Therapeutics can commercialize the drug globally except in Greater China and certain countries in East and Southeast Asia.Everest Medicines (Singapore) will receive an upfront payment of $112.5 million under the deal and up to $1.03 billion in development, regulatory, and commercial milestone payments across a maximum of five indications, alongside tiered royalties.Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases.

$HKG:1952